Technical Analysis for BXRX - Baudax Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical BXRX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.42% | |
| Down 3 Days in a Row | Weakness | 0.42% | |
| Lower Bollinger Band Touch | Weakness | 0.42% | |
| Oversold Stochastic | Weakness | 0.42% | |
| 50 DMA Resistance | Bearish | -7.69% | |
| Wide Bands | Range Expansion | -7.69% | |
| Oversold Stochastic | Weakness | -7.69% | |
| Fell Below 50 DMA | Bearish | -11.11% | |
| MACD Bearish Centerline Cross | Bearish | -11.11% | |
| 180 Bearish Setup | Bearish Swing Setup | -11.11% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Lower Bollinger Band Support | about 9 hours ago | |
| 1.5x Volume Pace | about 10 hours ago | |
| Fell Below Lower Bollinger Band | about 10 hours ago | |
| Down 10% | about 10 hours ago | |
| Down 5% | about 10 hours ago |
Get a Trading Assistant
- Earnings date: 02/16/2021
Baudax Bio, Inc. Description
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Drugs Clinical Trial Opioid Psychoactive Drugs Euphoriants Analgesics Orthopedic Surgery Neurochemistry Ketones Anxiolytics Colorectal Surgery Dexmedetomidine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.1791 |
| 52 Week Low | 0.1 |
| Average Volume | 6,813,581 |
| 200-Day Moving Average | 2.41 |
| 50-Day Moving Average | 1.37 |
| 20-Day Moving Average | 1.59 |
| 10-Day Moving Average | 1.42 |
| Average True Range | 0.18 |
| ADX | 21.22 |
| +DI | 16.78 |
| -DI | 29.96 |
| Chandelier Exit (Long, 3 ATRs ) | 1.59 |
| Chandelier Exit (Short, 3 ATRs ) | 1.68 |
| Upper Bollinger Band | 2.02 |
| Lower Bollinger Band | 1.16 |
| Percent B (%b) | 0.05 |
| BandWidth | 54.45 |
| MACD Line | -0.04 |
| MACD Signal Line | 0.02 |
| MACD Histogram | -0.0613 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.40 | ||||
| Resistance 3 (R3) | 1.40 | 1.34 | 1.36 | ||
| Resistance 2 (R2) | 1.34 | 1.29 | 1.34 | 1.35 | |
| Resistance 1 (R1) | 1.27 | 1.26 | 1.24 | 1.27 | 1.34 |
| Pivot Point | 1.21 | 1.21 | 1.20 | 1.21 | 1.21 |
| Support 1 (S1) | 1.14 | 1.16 | 1.11 | 1.14 | 1.06 |
| Support 2 (S2) | 1.08 | 1.13 | 1.08 | 1.05 | |
| Support 3 (S3) | 1.01 | 1.08 | 1.04 | ||
| Support 4 (S4) | 1.01 |
